Hatake, Kiyohiko
Ogura, Michinori
Takada, Kohichi
Taniwaki, Masafumi
Zhang, Fanghong
Fujita, Taizo
Ando, Kiyoshi
Funding for this research was provided by:
GlaxoSmithKline and Genmab
Article History
Received: 27 December 2016
Revised: 30 March 2017
Accepted: 4 April 2017
First Online: 18 April 2017
Compliance with ethical standards
:
: K Hatake has no conflicts of interest to declare. M. Taniwaki has received research funding from Chugai Pharmaceutical Co., Ltd. M. Ogura has received honoraria from Takeda Pharmaceuticals, Janssen Pharmaceuticals K.K and AstraZeneca K.K., and research funding from Eisai Co., Ltd., Takeda Pharmaceuticals, SymBio Pharmaceuticals, Janssen Pharmaceuticals K.K, and Chugai Pharmaceuticals Co., Ltd. K. Takada has no conflicts of interest to declare. K. Ando has received research funding from Renascience Co., Ltd. and Alexion Pharmaceuticals Inc., as well as subsidies or donations from Bristol-Myers Squibb, Kyowa Kirin, Mochida Pharmaceutical Co., Toyama Chemical Co., Ltd., Meiji Seika Pharma Co., Ltd, Chugai Pharmaceutical Co., Ltd., and Eisai Co., Ltd.
Free to read: This content has been made available to all.